- Competitive Grants Program Application Period to Begin on June 15, 2022 -
DUBLIN, June 2, 2022 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that the company will accept applications for its Alkermes Inspiration Grants program beginning on June 15, 2022. Now in its sixth year, this competitive grant program will provide up to a total of $500,000 in grants to assist nonprofit organizations in their work to address the needs of people living with addiction, serious mental illness or cancer.
"In addition to our work developing new medicines designed to address the real world needs of patients, we are committed to working toward positive change for people affected by addiction, serious mental illness or cancer," said Richard Pops, Chief Executive Officer of Alkermes. "This year, we have sharpened the focus of the Alkermes Inspiration Grants program to support innovative programs focused on unmet patient and caregiver needs, while continuing to prioritize efforts to address longstanding and widespread health disparities."
This year's submissions will be evaluated based on the set of criteria outlined in the request for proposals, with a focus on people affected by alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder, melanoma or ovarian cancer. Proposals should include clearly defined needs, objectives, activity format, mode of delivery and intended audience, and be relevant to historically under-resourced or underrepresented communities. Alkermes seeks to support programs that have a broad reach within the U.S. and potential to lead to sustained impact. Grant recipients will be selected by a committee that includes senior leaders from Alkermes and individuals chosen to represent the perspectives of people with lived experience, caregivers and patient advocates.
Eligible U.S. 501(c)(3) nonprofit organizations may submit a grant application between June 15, 2022 and July 15, 2022. For more information on the Alkermes Inspiration Grants program, including submission instructions, additional eligibility guidelines, evaluation criteria and a link to the application portal, please visit https://www.alkermes.com/responsibility/alkermes-inspiration-grants-2022.
Alkermes plc is a fully-integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for cancer and neurodegenerative disorders. Headquartered in Dublin, Ireland, Alkermes plc has a research and development center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes' website at www.alkermes.com.
ALKERMES INSPIRATION GRANTS is a registered service mark of Alkermes, Inc.
Alkermes Contacts:
For Investors: Alex Braun, +1 781 296 9493
For Media: Gretchen Murphy, +1 781 609 6419
